Biological impact of manual blood exchange in malignant Bordetella pertussis infection in infants.
Bordetella pertussis
PICU
blood exchange
hyperleukocytosis
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
revised:
23
06
2024
received:
22
03
2024
accepted:
19
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
aheadofprint
Résumé
Manual blood exchange (MBE) is a leukoreduction therapy for hyperleukocytosis in Bordetella spp. We describe the impact of BE on clinical and biological parameters in critically ill children with malignant pertussis. This is a monocentric retrospective review of patients with malignant pertussis infection treated with MBE. It describes the evolution of haemodynamic, ventilatory, haematologic and metabolic characteristics before and after MBE. Between January 2006 and December 2021, nine patients (median age 43 days, range: 13-80 days) had 16 MBE for malignant pertussis. All patients were mechanically ventilated, and 7/9 patients developed pulmonary hypertension during their paediatric intensive care unit (PICU) stay. Overall, 3/9 patients survived, and the mean PICU length of stay was 8.5 days (range: 1-52 days). We found a significant reduction of the leukocyte count (pre-MBE: 61.8 G/L [interquartile range (IQR): 55.8-74.8] vs. post-MBE: 19.4 G/L [IQR: 17.7-24.1]; p ≤ 0.001) and significant oxygenation improvement (pre-MBE SpO MBE efficiently reduces leukocytes and improves oxygenation in severe Bordetella pertussis infection in infants. Careful monitoring of calcium and thrombocytes seems mandatory.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Manual blood exchange (MBE) is a leukoreduction therapy for hyperleukocytosis in Bordetella spp.
INFECTION
BACKGROUND
We describe the impact of BE on clinical and biological parameters in critically ill children with malignant pertussis.
MATERIALS AND METHODS
METHODS
This is a monocentric retrospective review of patients with malignant pertussis infection treated with MBE. It describes the evolution of haemodynamic, ventilatory, haematologic and metabolic characteristics before and after MBE.
RESULTS
RESULTS
Between January 2006 and December 2021, nine patients (median age 43 days, range: 13-80 days) had 16 MBE for malignant pertussis. All patients were mechanically ventilated, and 7/9 patients developed pulmonary hypertension during their paediatric intensive care unit (PICU) stay. Overall, 3/9 patients survived, and the mean PICU length of stay was 8.5 days (range: 1-52 days). We found a significant reduction of the leukocyte count (pre-MBE: 61.8 G/L [interquartile range (IQR): 55.8-74.8] vs. post-MBE: 19.4 G/L [IQR: 17.7-24.1]; p ≤ 0.001) and significant oxygenation improvement (pre-MBE SpO
CONCLUSION
CONCLUSIONS
MBE efficiently reduces leukocytes and improves oxygenation in severe Bordetella pertussis infection in infants. Careful monitoring of calcium and thrombocytes seems mandatory.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Merdrignac L, Aït el Belghiti F, Pandolfi E, Jané M, Murphy J, Fabiánová K, et al. Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance system, December 2015 to December 2018. Euro Surveill. 2021;26:26.
Chantreuil J, Fakhri N, Labarthe F, Saliba E, Favrais G. Coqueluche maligne et exsanguino‐transfusion [Malignant pertussis and exchange transfusion]. Arch Pediatr. 2015;22:84–87.
Berger JT, Carcillo JA, Shanley TP, Wessel DL, Clark A, Holubkov R, et al. Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med. 2013;14:356–365.
Namachivayam P, Shimizu K, Butt W. Pertussis: severe clinical presentation in pediatric intensive care and its relation to outcome. Pediatr Crit Care Med. 2007;8:207–211.
Coquaz‐Garoudet M, Ploin D, Pouyau R, Hoffmann Y, Baleine JF, Boeuf B, et al. Malignant pertussis in infants: factors associated with mortality in a multicenter cohort study. Ann Intensive Care. 2021;11:70.
Ganeshalingham A, McSharry B, Anderson B, Grant C, Beca J. Identifying children at risk of malignant Bordetella pertussis infection. Pediatr Crit Care Med. 2017;18:e42–e47.
Marshall H, Clarke M, Rasiah K, Richmond P, Buttery J, Reynolds G, et al. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediatr Infect Dis J. 2015;34:339–345.
George TI. Malignant or benign leukocytosis. Hematology Am Soc Hematol Educ Program. 2012;2012:475–484.
Carbonetti NH. Pertussis leukocytosis: mechanisms, clinical relevance and treatment. Pathog Dis. 2016;74:74.
Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, Tatti KM, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47:328–338.
Rowlands HE, Goldman AP, Harrington K, Karimova A, Brierley J, Cross N, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics. 2010;126:e816–e827.
Son PT, Reda A, Viet DC, Quynh NXT, Hung DT, Tung TH, et al. Exchange transfusion in the management of critical pertussis in young infants: a case series. Vox Sang. 2021;116:976–982.